Mr Peter R. Culpepper United States

Provectus Biopharmaceuticals, Inc., specializes in developing oncology and dermatology therapies. PV-10, its novel investigational drug for cancer, is designed for injection into solid tumors (intralesional administration), thereby reducing potential for systemic side effects. Its oncology focus in on melanoma, breast cancer and cancers of the liver. The Company has received orphan drug designations from the FDA for its melanoma and hepatocellular carcinoma indications. PH-10, its topical investigational drug for dermatology, is undergoing clinical testing for psoriasis and atopic dematitis. Provectus has completed Phase 2 trials of PV-10 as a therapy for metastatic melanoma, and of PH10 as a topical treatment for atopic dermatitis and psoriasis.

Website:
www.pvct.com
Company Type
Company ticker
PVCT
Other Sector
Bipharmaceuticals
Keywords

oncology, dermatology, melanoma, solid tumors, intralesional, cancer, breast cancer, liver cancer, Phase III, atopic dermatitis, psoriasis, immunotherapy

Year Founded
2002
Management Team

H. Craig Dees, Ph.D., Chief Executive Officer; Timothy C. Scott, Ph.D., President; Eric A. Wachter, Ph.D., Chief Technology Officer; Peter R. Culpepper, Chief Financial Officer and Chief Operating Officer.

Mr Peter R. Culpepper
Provectus Biopharmaceuticals, Inc.
Interim CEO 
Presentation Time and Location:
16th, 11:00, Room: Panorama B
Biography

Pete Culpepper has spent 20 years in the financial field working for a wide range of companies and industries in the U.S. and abroad, especially high-growth startups. His experience with for-profit companies ranges from private start-ups to publicly traded, global conglomerates. He also has worked with large non-profits and a national CPA accounting firm. He led the national operating unit of a $1 billion publicly traded telecommunications company, as well as numerous operating units in Eastern Europe for a global telecommunications company. He handled the capital reporting process for a $5 billion global construction project and the formation of systems for a division that grew $150 million in revenue in two years. Previous employers include Neptec, Inc., a privately held optical networking component manufacturer; Metromedia Companies; and PageNet, the largest wireless messaging company in the world. Culpepper taught undergraduate and graduate business courses for the University of Phoenix Online. He is licensed as a Certified Public Accountant in Maryland and Tennessee. His professional affiliations include the American Institute of Certified Public Accountants, Financial Executives International and the Financial Executives Networking Group. Culpepper holds a master's of business administration (MBA) in finance from the University of Maryland. He earned an AAS in Accounting from the Northern Virginia Community College - Annandale, Virginia. He earned a bachelor's degree in philosophy from the College of William and Mary.

MSc Chresten Hedegaard United States

Provectus Biopharmaceuticals, Inc., specializes in developing oncology and dermatology therapies. PV-10, its novel investigational drug for cancer, is designed for injection into solid tumors (intralesional administration), thereby reducing potential for systemic side effects. Its oncology focus in on melanoma, breast cancer and cancers of the liver. The Company has received orphan drug designations from the FDA for its melanoma and hepatocellular carcinoma indications. PH-10, its topical investigational drug for dermatology, is undergoing clinical testing for psoriasis and atopic dematitis. Provectus has completed Phase 2 trials of PV-10 as a therapy for metastatic melanoma, and of PH10 as a topical treatment for atopic dermatitis and psoriasis.

Website:
www.pvct.com
Company Type
Company ticker
PVCT
Other Sector
Bipharmaceuticals
Keywords

oncology, dermatology, melanoma, solid tumors, intralesional, cancer, breast cancer, liver cancer, Phase III, atopic dermatitis, psoriasis, immunotherapy

Year Founded
2002
Management Team

H. Craig Dees, Ph.D., Chief Executive Officer; Timothy C. Scott, Ph.D., President; Eric A. Wachter, Ph.D., Chief Technology Officer; Peter R. Culpepper, Chief Financial Officer and Chief Operating Officer.

Provectus Biopharmaceuticals, Inc.
Coordinator 
Biography

Coordinator, Asia & Europe

Exploring investors and health care industrys interest in Provectus